Guardant Health acquired Bellwether Bio, Inc., a transaction announced in March 2019, structured as Acquisition (definitive agreement).
Bellwether Bio, Inc. is based in United States. Bellwether Bio is a privately held company pioneering research into the epigenomic content of cell-free DNA to improve oncology patient care. Guardant Health acquired it to bolster its epigenomics capabilities for blood-based cancer detection.
Strengthen Guardant Health's epigenomic cell-free DNA technology for precision oncology.
Advisory firms were not disclosed for this transaction.